论文部分内容阅读
目的:从没有在中国得到保护的美国专利申请或专利中寻找心血管疾病治疗药物研发的思路。方法:对申请日从2005年1月1日至2014年12月31日的美国心血管系统疾病治疗药物PCT申请进入中国国家阶段后失效的专利申请及专利数据进行整序和分析,依据其在美国本土的法律状态确定其技术含金量。结果:未得到中国专利保护的美国心血管系统疾病治疗药物PCT申请共174件,其中170件申请了美国优先权或进入了美国国家阶段。结论:170件美国心血管系统疾病治疗药物PCT申请在美国申请优先权,大多数因美国的优先权临时申请过期而放弃。14件在美国本土的优先权申请失效,其所含信息量应该相当于公开发表的论文的信息量,23件在美国本土优先权授权的专利技术具有一定的技术含金量,目前在中国已经进入公知公用领域,经过市场价值评估后可以无偿使用。
OBJECTIVES: To seek ideas for the development of therapeutics for cardiovascular diseases from US patent applications or patents that are not protected in China. METHODS: The patent applications and patent data that failed to enter the national phase of PCT application for the treatment of cardiovascular disease in the United States from January 1, 2005 to December 31, 2014 were sequenced and analyzed according to The legal status of the United States to determine its technical gold content. Results: There were 174 PCT applications for the treatment of cardiovascular diseases in the United States that were not protected by Chinese patents, of which 170 had applied for U.S. priority or entered the U.S. national phase. CONCLUSIONS: The 170 PCT applications for the treatment of cardiovascular disease in the United States applied for priority in the United States, the majority of which were abandoned due to the expiration of the priority provisional application in the United States. Fourteen applications for priority applications in the United States lapsed, the amount of information contained in them should be equivalent to that of published papers, 23 patented technologies with priority rights in the United States have a certain amount of technical content and are now well known in China Public domain, after market valuation can be used free of charge.